Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.

Show Nav →
Please include the following statement when referencing the CPTAC Assay Portal
We would like to acknowledge the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) Assay Portal (assays.cancer.gov) for developing assays and establishing criteria for the assays described in this publication.

LPA

Previous Assay Next Assay
Available Assays

Overview Data source: UniProt

Official Gene Symbol Other Aliases
LPA N/A
Sequence Length (AA) Molecular Weight (Da)
4548 501319
Protein Name
Apolipoprotein(a)
Sources
UniProt
PhosphoSitePlus ®
GeneCards 		Human Protein Atlas

Protein Sequence hover to view complete sequence

10 20 30 40 50
MEHKEVVLLL LLFLKSAAPE QSHVVQDCYH GDGQSYRGTY STTVTGRTCQ
60 70 80 90 100
AWSSMTPHQH NRTTENYPNA GLIMNYCRNP DAVAAPYCYT RDPGVRWEYC
110 120 130 140 150
NLTQCSDAEG TAVAPPTVTP VPSLEAPSEQ APTEQRPGVQ ECYHGNGQSY
160 170 180 190 200
RGTYSTTVTG RTCQAWSSMT PHSHSRTPEY YPNAGLIMNY CRNPDAVAAP
210 220 230 240 250
YCYTRDPGVR WEYCNLTQCS DAEGTAVAPP TVTPVPSLEA PSEQAPTEQR
260 270 280 290 300
PGVQECYHGN GQSYRGTYST TVTGRTCQAW SSMTPHSHSR TPEYYPNAGL
310 320 330 340 350
IMNYCRNPDA VAAPYCYTRD PGVRWEYCNL TQCSDAEGTA VAPPTVTPVP
360 370 380 390 400
SLEAPSEQAP TEQRPGVQEC YHGNGQSYRG TYSTTVTGRT CQAWSSMTPH
410 420 430 440 450
SHSRTPEYYP NAGLIMNYCR NPDAVAAPYC YTRDPGVRWE YCNLTQCSDA
460 470 480 490 500
EGTAVAPPTV TPVPSLEAPS EQAPTEQRPG VQECYHGNGQ SYRGTYSTTV
510 520 530 540 550
TGRTCQAWSS MTPHSHSRTP EYYPNAGLIM NYCRNPDAVA APYCYTRDPG
560 570 580 590 600
VRWEYCNLTQ CSDAEGTAVA PPTVTPVPSL EAPSEQAPTE QRPGVQECYH
610 620 630 640 650
GNGQSYRGTY STTVTGRTCQ AWSSMTPHSH SRTPEYYPNA GLIMNYCRNP
660 670 680 690 700
DAVAAPYCYT RDPGVRWEYC NLTQCSDAEG TAVAPPTVTP VPSLEAPSEQ
710 720 730 740 750
APTEQRPGVQ ECYHGNGQSY RGTYSTTVTG RTCQAWSSMT PHSHSRTPEY
760 770 780 790 800
YPNAGLIMNY CRNPDAVAAP YCYTRDPGVR WEYCNLTQCS DAEGTAVAPP
810 820 830 840 850
TVTPVPSLEA PSEQAPTEQR PGVQECYHGN GQSYRGTYST TVTGRTCQAW
860 870 880 890 900
SSMTPHSHSR TPEYYPNAGL IMNYCRNPDA VAAPYCYTRD PGVRWEYCNL
910 920 930 940 950
TQCSDAEGTA VAPPTVTPVP SLEAPSEQAP TEQRPGVQEC YHGNGQSYRG
960 970 980 990 1000
TYSTTVTGRT CQAWSSMTPH SHSRTPEYYP NAGLIMNYCR NPDAVAAPYC
1010 1020 1030 1040 1050
YTRDPGVRWE YCNLTQCSDA EGTAVAPPTV TPVPSLEAPS EQAPTEQRPG
1060 1070 1080 1090 1100
VQECYHGNGQ SYRGTYSTTV TGRTCQAWSS MTPHSHSRTP EYYPNAGLIM
1110 1120 1130 1140 1150
NYCRNPDAVA APYCYTRDPG VRWEYCNLTQ CSDAEGTAVA PPTVTPVPSL
1160 1170 1180 1190 1200
EAPSEQAPTE QRPGVQECYH GNGQSYRGTY STTVTGRTCQ AWSSMTPHSH
1210 1220 1230 1240 1250
SRTPEYYPNA GLIMNYCRNP DAVAAPYCYT RDPGVRWEYC NLTQCSDAEG
1260 1270 1280 1290 1300
TAVAPPTVTP VPSLEAPSEQ APTEQRPGVQ ECYHGNGQSY RGTYSTTVTG
1310 1320 1330 1340 1350
RTCQAWSSMT PHSHSRTPEY YPNAGLIMNY CRNPDAVAAP YCYTRDPGVR
1360 1370 1380 1390 1400
WEYCNLTQCS DAEGTAVAPP TVTPVPSLEA PSEQAPTEQR PGVQECYHGN
1410 1420 1430 1440 1450
GQSYRGTYST TVTGRTCQAW SSMTPHSHSR TPEYYPNAGL IMNYCRNPDA
1460 1470 1480 1490 1500
VAAPYCYTRD PGVRWEYCNL TQCSDAEGTA VAPPTVTPVP SLEAPSEQAP
1510 1520 1530 1540 1550
TEQRPGVQEC YHGNGQSYRG TYSTTVTGRT CQAWSSMTPH SHSRTPEYYP
1560 1570 1580 1590 1600
NAGLIMNYCR NPDAVAAPYC YTRDPGVRWE YCNLTQCSDA EGTAVAPPTV
1610 1620 1630 1640 1650
TPVPSLEAPS EQAPTEQRPG VQECYHGNGQ SYRGTYSTTV TGRTCQAWSS
1660 1670 1680 1690 1700
MTPHSHSRTP EYYPNAGLIM NYCRNPDAVA APYCYTRDPG VRWEYCNLTQ
1710 1720 1730 1740 1750
CSDAEGTAVA PPTVTPVPSL EAPSEQAPTE QRPGVQECYH GNGQSYRGTY
1760 1770 1780 1790 1800
STTVTGRTCQ AWSSMTPHSH SRTPEYYPNA GLIMNYCRNP DAVAAPYCYT
1810 1820 1830 1840 1850
RDPGVRWEYC NLTQCSDAEG TAVAPPTVTP VPSLEAPSEQ APTEQRPGVQ
1860 1870 1880 1890 1900
ECYHGNGQSY RGTYSTTVTG RTCQAWSSMT PHSHSRTPEY YPNAGLIMNY
1910 1920 1930 1940 1950
CRNPDAVAAP YCYTRDPGVR WEYCNLTQCS DAEGTAVAPP TVTPVPSLEA
1960 1970 1980 1990 2000
PSEQAPTEQR PGVQECYHGN GQSYRGTYST TVTGRTCQAW SSMTPHSHSR
2010 2020 2030 2040 2050
TPEYYPNAGL IMNYCRNPDA VAAPYCYTRD PGVRWEYCNL TQCSDAEGTA
2060 2070 2080 2090 2100
VAPPTVTPVP SLEAPSEQAP TEQRPGVQEC YHGNGQSYRG TYSTTVTGRT
2110 2120 2130 2140 2150
CQAWSSMTPH SHSRTPEYYP NAGLIMNYCR NPDAVAAPYC YTRDPGVRWE
2160 2170 2180 2190 2200
YCNLTQCSDA EGTAVAPPTV TPVPSLEAPS EQAPTEQRPG VQECYHGNGQ
2210 2220 2230 2240 2250
SYRGTYSTTV TGRTCQAWSS MTPHSHSRTP EYYPNAGLIM NYCRNPDAVA
2260 2270 2280 2290 2300
APYCYTRDPG VRWEYCNLTQ CSDAEGTAVA PPTVTPVPSL EAPSEQAPTE
2310 2320 2330 2340 2350
QRPGVQECYH GNGQSYRGTY STTVTGRTCQ AWSSMTPHSH SRTPEYYPNA
2360 2370 2380 2390 2400
GLIMNYCRNP DAVAAPYCYT RDPGVRWEYC NLTQCSDAEG TAVAPPTVTP
2410 2420 2430 2440 2450
VPSLEAPSEQ APTEQRPGVQ ECYHGNGQSY RGTYSTTVTG RTCQAWSSMT
2460 2470 2480 2490 2500
PHSHSRTPEY YPNAGLIMNY CRNPDAVAAP YCYTRDPGVR WEYCNLTQCS
2510 2520 2530 2540 2550
DAEGTAVAPP TVTPVPSLEA PSEQAPTEQR PGVQECYHGN GQSYRGTYST
2560 2570 2580 2590 2600
TVTGRTCQAW SSMTPHSHSR TPEYYPNAGL IMNYCRNPDA VAAPYCYTRD
2610 2620 2630 2640 2650
PGVRWEYCNL TQCSDAEGTA VAPPTVTPVP SLEAPSEQAP TEQRPGVQEC
2660 2670 2680 2690 2700
YHGNGQSYRG TYSTTVTGRT CQAWSSMTPH SHSRTPEYYP NAGLIMNYCR
2710 2720 2730 2740 2750
NPDAVAAPYC YTRDPGVRWE YCNLTQCSDA EGTAVAPPTV TPVPSLEAPS
2760 2770 2780 2790 2800
EQAPTEQRPG VQECYHGNGQ SYRGTYSTTV TGRTCQAWSS MTPHSHSRTP
2810 2820 2830 2840 2850
EYYPNAGLIM NYCRNPDAVA APYCYTRDPG VRWEYCNLTQ CSDAEGTAVA
2860 2870 2880 2890 2900
PPTVTPVPSL EAPSEQAPTE QRPGVQECYH GNGQSYRGTY STTVTGRTCQ
2910 2920 2930 2940 2950
AWSSMTPHSH SRTPEYYPNA GLIMNYCRNP DAVAAPYCYT RDPGVRWEYC
2960 2970 2980 2990 3000
NLTQCSDAEG TAVAPPTVTP VPSLEAPSEQ APTEQRPGVQ ECYHGNGQSY
3010 3020 3030 3040 3050
RGTYSTTVTG RTCQAWSSMT PHSHSRTPEY YPNAGLIMNY CRNPDAVAAP
3060 3070 3080 3090 3100
YCYTRDPGVR WEYCNLTQCS DAEGTAVAPP TVTPVPSLEA PSEQAPTEQR
3110 3120 3130 3140 3150
PGVQECYHGN GQSYRGTYST TVTGRTCQAW SSMTPHSHSR TPEYYPNAGL
3160 3170 3180 3190 3200
IMNYCRNPDA VAAPYCYTRD PGVRWEYCNL TQCSDAEGTA VAPPTVTPVP
3210 3220 3230 3240 3250
SLEAPSEQAP TEQRPGVQEC YHGNGQSYRG TYSTTVTGRT CQAWSSMTPH
3260 3270 3280 3290 3300
SHSRTPEYYP NAGLIMNYCR NPDAVAAPYC YTRDPGVRWE YCNLTQCSDA
3310 3320 3330 3340 3350
EGTAVAPPTV TPVPSLEAPS EQAPTEQRPG VQECYHGNGQ SYRGTYSTTV
3360 3370 3380 3390 3400
TGRTCQAWSS MTPHSHSRTP EYYPNAGLIM NYCRNPDPVA APYCYTRDPS
3410 3420 3430 3440 3450
VRWEYCNLTQ CSDAEGTAVA PPTITPIPSL EAPSEQAPTE QRPGVQECYH
3460 3470 3480 3490 3500
GNGQSYQGTY FITVTGRTCQ AWSSMTPHSH SRTPAYYPNA GLIKNYCRNP
3510 3520 3530 3540 3550
DPVAAPWCYT TDPSVRWEYC NLTRCSDAEW TAFVPPNVIL APSLEAFFEQ
3560 3570 3580 3590 3600
ALTEETPGVQ DCYYHYGQSY RGTYSTTVTG RTCQAWSSMT PHQHSRTPEN
3610 3620 3630 3640 3650
YPNAGLTRNY CRNPDAEIRP WCYTMDPSVR WEYCNLTQCL VTESSVLATL
3660 3670 3680 3690 3700
TVVPDPSTEA SSEEAPTEQS PGVQDCYHGD GQSYRGSFST TVTGRTCQSW
3710 3720 3730 3740 3750
SSMTPHWHQR TTEYYPNGGL TRNYCRNPDA EISPWCYTMD PNVRWEYCNL
3760 3770 3780 3790 3800
TQCPVTESSV LATSTAVSEQ APTEQSPTVQ DCYHGDGQSY RGSFSTTVTG
3810 3820 3830 3840 3850
RTCQSWSSMT PHWHQRTTEY YPNGGLTRNY CRNPDAEIRP WCYTMDPSVR
3860 3870 3880 3890 3900
WEYCNLTQCP VMESTLLTTP TVVPVPSTEL PSEEAPTENS TGVQDCYRGD
3910 3920 3930 3940 3950
GQSYRGTLST TITGRTCQSW SSMTPHWHRR IPLYYPNAGL TRNYCRNPDA
3960 3970 3980 3990 4000
EIRPWCYTMD PSVRWEYCNL TRCPVTESSV LTTPTVAPVP STEAPSEQAP
4010 4020 4030 4040 4050
PEKSPVVQDC YHGDGRSYRG ISSTTVTGRT CQSWSSMIPH WHQRTPENYP
4060 4070 4080 4090 4100
NAGLTENYCR NPDSGKQPWC YTTDPCVRWE YCNLTQCSET ESGVLETPTV
4110 4120 4130 4140 4150
VPVPSMEAHS EAAPTEQTPV VRQCYHGNGQ SYRGTFSTTV TGRTCQSWSS
4160 4170 4180 4190 4200
MTPHRHQRTP ENYPNDGLTM NYCRNPDADT GPWCFTMDPS IRWEYCNLTR
4210 4220 4230 4240 4250
CSDTEGTVVA PPTVIQVPSL GPPSEQDCMF GNGKGYRGKK ATTVTGTPCQ
4260 4270 4280 4290 4300
EWAAQEPHRH STFIPGTNKW AGLEKNYCRN PDGDINGPWC YTMNPRKLFD
4310 4320 4330 4340 4350
YCDIPLCASS SFDCGKPQVE PKKCPGSIVG GCVAHPHSWP WQVSLRTRFG
4360 4370 4380 4390 4400
KHFCGGTLIS PEWVLTAAHC LKKSSRPSSY KVILGAHQEV NLESHVQEIE
4410 4420 4430 4440 4450
VSRLFLEPTQ ADIALLKLSR PAVITDKVMP ACLPSPDYMV TARTECYITG
4460 4470 4480 4490 4500
WGETQGTFGT GLLKEAQLLV IENEVCNHYK YICAEHLARG TDSCQGDSGG
4510 4520 4530 4540 4548
PLVCFEKDKY ILQGVTSWGL GCARPNKPGV YARVSRFVTW IEGMMRNN

Data source: UniProt

Protein Map Collapse protein map

Position of Targeted Peptide Analytes Relative to SNPs, Isoforms, and PTMs

Uniprot Database Entry PhosphoSitePlus ®

Click a point on a node
to view detailed assay information below
All other points link out to UniProt


Phosphorylation Acetylation Ubiquitylation Other

loading

Loader

Assay Details for non-CPTAC-2622 Collapse assay details

Data source: Panorama

Official Gene Symbol
LPA
Peptide Sequence
LFLEPTQADIALLK
Modification Type
unmodified
Protein - Site of Modification
N/A
Peptide - Site of Modification
N/A
Peptide Start
4404
Peptide End
4417
CPTAC ID
non-CPTAC-2622
Peptide Molecular Mass
1,570.8970
Species
Homo sapiens (Human)
Assay Type
Direct MRM
Matrix
plasma
Submitting Laboratory
UVic-Genome BC Proteomics Centre
Submitting Lab PI
Christoph Borchers

Assay Parameters Collapse assay parameters

Data source: Panorama

Instrument
6490 Triple Quad (Agilent)
Internal Standard
synthetic peptide
Peptide Standard Purity
>95%
Peptide Standard Label Type
13C and 15N at C-terminus K
LC
1290 LC (Agilent)
Column Packing
Zorbax Eclipse Plus C18, 1.8 µm
Column Dimensions
2.1 x 150 mm
Flow Rate
400 µL/min

Chromatograms

Data source: Panorama

view larger image
view larger image
view larger image

Response Curves

Data source: Panorama

view larger image
view larger image
view larger image

Retrieving Data

Loader

Repeatability

Data source: Panorama

view larger image
  Average intra-assay CV
(within day CV)		 Average inter-assay CV
(between day CV)		 Total CV
equation		 n=
Fragment ion / Transition Low Med High Low Med High Low Med High Low Med High
y10 (2+) 6.5 6.1 12.3 15 9 16.9 16.3 10.9 20.9 15 15 15
y10 (1+) 6.2 4.7 10.7 11.6 11.4 11.2 13.2 12.3 15.5 15 15 15
b3 (1+) 6.1 7.3 8.6 12.9 10.2 11.5 14.3 12.5 14.4 15 15 15
b4 (1+) 10.5 5.3 9.6 13.6 8.6 13.2 17.2 10.1 16.3 15 15 15
sum 5.2 4.7 10.1 12.3 9.8 12.6 13.4 10.9 16.1 15 15 15

Additional Resources and Comments

Resources
Download SOPs
View Peptide in Panorama
View Protein in Panorama
Comments

Assay Details for non-CPTAC-2621 Collapse assay details

Data source: Panorama

Official Gene Symbol
LPA
Peptide Sequence
TPAYYPNAGLIK
Modification Type
unmodified
Protein - Site of Modification
N/A
Peptide - Site of Modification
N/A
Peptide Start
3483
Peptide End
3494
CPTAC ID
non-CPTAC-2621
Peptide Molecular Mass
1,306.6921
Species
Homo sapiens (Human)
Assay Type
Direct MRM
Matrix
plasma
Submitting Laboratory
UVic-Genome BC Proteomics Centre
Submitting Lab PI
Christoph Borchers

Assay Parameters Collapse assay parameters

Data source: Panorama

Instrument
6490 Triple Quad (Agilent)
Internal Standard
synthetic peptide
Peptide Standard Purity
>95%
Peptide Standard Label Type
13C and 15N at C-terminus K
LC
1290 LC (Agilent)
Column Packing
Zorbax Eclipse Plus C18, 1.8 µm
Column Dimensions
2.1 x 150 mm
Flow Rate
400 µL/min

Chromatograms

Data source: Panorama

view larger image
view larger image
view larger image

Response Curves

Data source: Panorama

view larger image
view larger image
view larger image

Retrieving Data

Loader

Repeatability

Data source: Panorama

view larger image
  Average intra-assay CV
(within day CV)		 Average inter-assay CV
(between day CV)		 Total CV
equation		 n=
Fragment ion / Transition Low Med High Low Med High Low Med High Low Med High
y7 (1+) 9.3 4.5 5.2 14.4 7.9 8 17.1 9.1 9.5 15 15 15
y2 (1+) 27.1 10.8 5.7 33.2 10.1 7 42.9 14.8 9 15 15 15
y11 (2+) 21.6 7.1 7.3 20.8 9.9 8.7 30 12.2 11.4 15 15 15
b3 (1+) 13.6 5.1 6.1 15.6 10.4 8 20.7 11.6 10.1 15 15 15
y8 (1+) 11.7 4.4 5.3 12.9 10.4 6.7 17.4 11.3 8.5 15 15 15
sum 5.9 3.1 4.5 8.6 8 6.8 10.4 8.6 8.2 15 15 15

Additional Resources and Comments

Resources
Download SOPs
View Peptide in Panorama
View Protein in Panorama
Comments